SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate